Venus Remedies Limited (VENUSREM.NS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-14.2%

₹1,137.99

vs ₹1,325.90 price

Levered DCF

₹1,018.85

After debt service

Piotroski score

4 / 9

Average

Altman Z-score

9.87

Safe zone

Rating

A-

Overall 4 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	10.67×	9.33×	15.88×	8.18×	8.76×	5.49×	-2.72×	-1.47×
P/B	1.65×	0.75×	0.93×	0.47×	0.82×	0.85×	0.08×	0.13×
P/S	1.42×	0.65×	0.76×	0.39×	0.6×	0.62×	0.08×	0.13×
EV / EBITDA	6.74×	3.65×	6.25×	3.39×	5.15×	3.73×	6.89×	11.4×
Gross margin	34.8%	25.7%	36.9%	40.4%	33.5%	19.6%	45.1%	39.4%
Operating margin	15.8%	6.3%	5.6%	4.9%	4.7%	2.0%	3.3%	-0.4%
Net margin	13.4%	7.0%	4.8%	4.8%	6.8%	11.3%	-3.0%	-9.0%
Current ratio	2.44×	3.31×	4.53×	3.91×	3×	2.4×	1.32×	1.01×
Debt / equity	0.02×	0×	0.08×	0.09×	0.1×	0.13×	0.68×	0.9×
Interest coverage	3,040.25×	586.14×	353.87×	231.52×	58.41×	0.84×	0.96×	-0.05×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	15.5%	8.1%	5.8%	5.8%	9.2%	15.4%	-3.1%	-8.6%
Return on invested capital	13.4%	4.5%	3.8%	3.7%	5.7%	2.3%	2.0%	-0.2%
Return on assets	12.0%	6.3%	4.5%	4.4%	7.0%	11.1%	-1.6%	-3.9%
Free cash flow yield	10.9%	19.2%	6.2%	13.3%	7.6%	36.8%	255.0%	84.3%
Earnings yield	9.4%	10.7%	6.3%	12.2%	11.3%	18.2%	-36.8%	-68.0%
Enterprise value	₹10.8B	₹3.4B	₹4.4B	₹2.4B	₹3.6B	₹3.6B	₹2.5B	₹3.4B
Net debt / EBITDA	-0.11×	-0.83×	-0.11×	0.3×	-0.01×	0.23×	6.13×	9.98×
Cash conversion cycle (days)	64	70	126	127	96	75	245	257